Free Trial
NASDAQ:DERM

Journey Medical (DERM) Stock Price, News & Analysis

Journey Medical logo
$6.13 -0.05 (-0.79%)
As of 09:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Journey Medical Stock (NASDAQ:DERM)

Key Stats

Today's Range
$6.29
$6.29
50-Day Range
$4.98
$7.19
52-Week Range
$3.20
$7.29
Volume
413 shs
Average Volume
80,994 shs
Market Capitalization
$141.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.88
Consensus Rating
Buy

Company Overview

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Remove Ads

Journey Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

DERM MarketRank™: 

Journey Medical scored higher than 48% of companies evaluated by MarketBeat, and ranked 483rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Journey Medical has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Journey Medical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Journey Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Journey Medical are expected to grow in the coming year, from ($1.02) to ($0.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Journey Medical is -6.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Journey Medical is -6.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Journey Medical has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Journey Medical's valuation and earnings.
  • Percentage of Shares Shorted

    1.50% of the float of Journey Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Journey Medical has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Journey Medical has recently increased by 27.96%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Journey Medical does not currently pay a dividend.

  • Dividend Growth

    Journey Medical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.50% of the float of Journey Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Journey Medical has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Journey Medical has recently increased by 27.96%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Journey Medical has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Journey Medical this week, compared to 2 articles on an average week.
  • Search Interest

    7 people have searched for DERM on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Journey Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $536,622.00 in company stock.

  • Percentage Held by Insiders

    13.16% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.25% of the stock of Journey Medical is held by institutions.

  • Read more about Journey Medical's insider trading history.
Receive DERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Journey Medical and its competitors with MarketBeat's FREE daily newsletter.

DERM Stock News Headlines

Journey Medical promotes Ramsey Alloush to COO
What to do with your collapsing portfolio…
There might be only one way to save your retirement in this volatile time. After watching investors lose $6 trillion in market cap in a matter of DAYS... And after seeing businesses bleeding dry as trade tensions spiral out of control... What the acclaimed “Market Wizard” Larry Benedict — who beat the market by 103% during the 2008 crash — is about to reveal could not only save your retirement from Trump's tariffs…
Journey Medical reports FY24 EPS (72c) vs (21c) last year
See More Headlines

DERM Stock Analysis - Frequently Asked Questions

Journey Medical's stock was trading at $3.91 at the beginning of 2025. Since then, DERM shares have increased by 56.8% and is now trading at $6.1310.
View the best growth stocks for 2025 here
.

Journey Medical Co. (NASDAQ:DERM) issued its quarterly earnings results on Wednesday, March, 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.30. The business earned $14.30 million during the quarter, compared to analysts' expectations of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative trailing twelve-month return on equity of 132.10%.
Read the conference call transcript
.

Journey Medical (DERM) raised $39 million in an IPO on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share.

Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Journey Medical investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Adobe (ADBE) and AppLovin (APP).

Company Calendar

Last Earnings
3/26/2025
Today
4/15/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DERM
Previous Symbol
NASDAQ:DERM
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.88
High Stock Price Target
$11.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+59.8%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,850,000.00
Pretax Margin
-31.52%

Debt

Sales & Book Value

Annual Sales
$56.13 million
Cash Flow
$0.22 per share
Price / Cash Flow
28.37
Book Value
$1.05 per share
Price / Book
5.89

Miscellaneous

Free Float
18,141,000
Market Cap
$142.78 million
Optionable
N/A
Beta
0.90
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:DERM) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners